Himachal regulators bust alleged fake pharma unit using forged licences
Drug regulators in Himachal Pradesh have busted Dr. Trustmed, an alleged fake pharmaceutical entity accused of using forged licences, quality certificates and labels to collect advance payments. The case flags supplier-verification risks for medicine distributors and traders in the Baddi cluster.
What happened
Himachal Pradesh drug regulators busted fake pharma entity Dr. Trustmed for using forged licences, quality certificates and labels to collect advance payments.
Key facts
- India's pharmaceutical industry is valued at over $60 billion
- India supplies nearly 20% of global generic medicines
- India supplies over 60% of global vaccines
Why this matters
Pharma buyers and partners should expand pre-deal diligence to independently verify licences, quality certificates, label ownership and regulatory inspection histories.
What to watch
- Regulator disclosures naming additional companies, distributors, licence numbers, products or counterfeit batches.
- Drug-control department orders for recalls, stop-sale notices, sample failures or licence cancellations.
- Police filings indicating forged-document networks, payment-account trails or involvement of label printers and logistics providers.
- Unusual price discounts, urgent advance-payment demands, changed bank accounts or reluctance to permit factory inspections from Baddi suppliers.
- Increased inspection frequency, document-verification mandates or trade-association advisories affecting Himachal pharmaceutical units.
- Customer complaints, adverse-event reports or pharmacy returns tied to products supplied through the implicated network.
- Immediately suspend new advance payments to unverified Baddi-cluster suppliers and reconcile outstanding deposits, purchase orders and dispatch records.
- Require direct verification of manufacturing and wholesale drug licences through regulator records rather than supplier-provided copies.
- Match GMP/quality certificates, product approvals, batch numbers, test reports, labels and manufacturer addresses against official databases and physical-site checks.
- Tighten vendor onboarding with beneficial-owner, GST, bank-account-name and reference checks; flag recently changed payment instructions.
- Quarantine any stock sourced from the entity or linked intermediaries pending batch-level authenticity and quality review.
- Build dual sourcing for critical SKUs to offset potential disruption if enforcement expands across connected suppliers.